WCN26-3469 OBINUTUZUMAB INDUCES HISTOLOGIC REMISSION AND DEEP KIDNEY PARENCHYMAL B-CELL DEPLETION IN PATIENTS WITH LUPUS NEPHRITIS: EXPLORATORY ANALYSES FROM THE REGENCY TRIAL

Read full text Summarise with VIRAT
Authors: Brad H. Rovin, Elsa Martins, Cary D. Austin, Harini Raghu, Caleb K. Chan, Patrick S. Chang, Valeria Gabriela Alberton, Mittermayer B. Santiago, Gustavo Aroca-Martinez, José Alfaro, Richard Alan Furie, Christopher Larson
+3 more Bongin Yoo, William Franklin Pendergraft, Ana Malvar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). It was postulated that OBI+ST would yield greater rates of histologic remission and kidney tissue-level B-cell depletion at W76 than PBO+ST, which would portend more favorable long-term kidney outcomes, such as reduced LN flare risk and preserved kidney function. These exploratory analyses aimed to evaluate histologic remission and kidney tissue-level B-cell depletion at W76 in patients treated with OBI+ST vs PBO+ST.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106200–106200
Publication date
25 March 2026
Language
EN